Single Sample Pap/HPV/Chlamydia/GC

NYS Dept. of Health Approves Sunrise’s Method for the Detection of C. trachomatis and N. gonorrhea in ThinPrep Samples

Hauppauge, NY, February 4, 2003 — Sunrise Medical Laboratories, Inc. announced today that the New York State Department of Health has approved its method for the detection of C. trachomatis and N. gonorrhea in Cytyc ThinPrep Samples, a modification of the FDA-cleared test.

Larry Siedlick, CEO of Sunrise Medical Laboratories, stated, "This is a dawn of a new era in women’s health. It is a major breakthrough in simplifying collection, improving detection and patient outcomes. A single sample can now be used for a Pap test, Human Papilloma Virus (HPV), C. trachomatis and N. gonorrhea.”

“We are extremely proud of our scientific team who conducted the validation studies and are gratified that, after review by New York State Department of Health scientists, the method was approved.”

A Nucleic Acid Amplification Test (NAAT) that utilizes target capture followed by Transcription-Mediated Amplification (TMA) and Dual Kinetic Assay detection the test offers higher sensitivity and specificity for both CT and GC than other testing methods. It is a highly effective tool for infections in asymptomatic individuals.

This new procedure provides an easy way to meet CDC recommendations for routine screening of sexually active women for Chlamydia/GC.

The benefits of this breakthrough technology are clear:
Single Patient Sample - Greater Diagnostic Confidence.

BACK TO PRESS RELEASES